158 related articles for article (PubMed ID: 3744134)
1. On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure.
Lane DA; Flynn A; Ireland H; Anastassiades E; Curtis JR
Haemostasis; 1986; 16 Suppl 2():38-47. PubMed ID: 3744134
[TBL] [Abstract][Full Text] [Related]
2. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
3. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment.
Ireland H; Lane DA; Flynn A; Anastassiades E; Curtis JR
Thromb Haemost; 1986 Apr; 55(2):271-5. PubMed ID: 3715791
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR
Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924
[TBL] [Abstract][Full Text] [Related]
5. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin.
Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR
Nephrol Dial Transplant; 1990; 5(2):135-40. PubMed ID: 2162506
[TBL] [Abstract][Full Text] [Related]
6. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
[TBL] [Abstract][Full Text] [Related]
7. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis.
Ryan KE; Lane DA; Flynn A; Shepperd J; Ireland HA; Curtis JR
Thromb Haemost; 1991 Sep; 66(3):277-82. PubMed ID: 1745997
[TBL] [Abstract][Full Text] [Related]
8. Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients.
Schrader J; Kandt M; Zürcher C; Köstering H; Scheler F
Haemostasis; 1986; 16 Suppl 2():48-58. PubMed ID: 3091459
[TBL] [Abstract][Full Text] [Related]
9. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
[TBL] [Abstract][Full Text] [Related]
10. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
[TBL] [Abstract][Full Text] [Related]
11. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
Ljungberg B; Blombäck M; Johnsson H; Lins LE
Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906
[TBL] [Abstract][Full Text] [Related]
12. Objective assessment of heparin requirements for hemodialysis in humans.
Ireland H; Lane DA; Curtis JR
J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409
[TBL] [Abstract][Full Text] [Related]
13. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222.
Tew CJ; Lane DA; Thompson E; Ireland H; Curtis JR
Br J Haematol; 1988 Nov; 70(3):335-40. PubMed ID: 2849981
[TBL] [Abstract][Full Text] [Related]
14. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin.
Gallino A; Haeberli A; Hess T; Mombelli G; Straub PW
Am Heart J; 1986 Aug; 112(2):285-90. PubMed ID: 2426934
[TBL] [Abstract][Full Text] [Related]
15. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
Lane DA; Ireland H; Tew CJ; Flynn A; Curtis JR
Acta Chir Scand Suppl; 1988; 543():101-4. PubMed ID: 2847457
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin half life is prolonged in haemodialysed patients.
Goudable C; Ton That H; Damani A; Durand D; Caranobe C; Sié P; Boneu B
Thromb Res; 1986 Jul; 43(1):1-5. PubMed ID: 3726807
[No Abstract] [Full Text] [Related]
17. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
[TBL] [Abstract][Full Text] [Related]
18. The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.
Gunnarsson B; Asaba H; Dawidson S; Wilhelmsson S; Bergström J
Clin Nephrol; 1981 Mar; 15(3):135-42. PubMed ID: 7273488
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR
Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
